RG
RVMD icon

Redmile Group’s Revolution Medicines RVMD Stock Holding History

Redmile Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-625,000
Closed -$14.9M – 79
2022
Q4 		$14.9M Hold
625,000
– – 0.61% 43
2022
Q3 		$12.3M Buy
+625,000
New +$13.7M 0.48% 48
2020
Q2 		– Sell
-303,371
Closed -$6.65M – 85
2020
Q1 		$6.65M Buy
+303,371
New +$8.4M 0.19% 58

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Redmile Group's RVMD Position: Q1 2023 in Review

Redmile Group sold out of Revolution Medicines (RVMD) in Q1 2023, closing a stake of 625,000 shares — an estimated $14.9M sold.

Redmile Group first reported a position in RVMD in Q1 2020 and held it in 3 quarters. The position peaked at $14.9M in Q4 2022. 152 funds tracked by Wall St. Rank hold RVMD as of Q1 2023.

  • Redmile Group reported no remaining Revolution Medicines position as of Q1 2023 after selling out during the quarter.
  • Redmile Group sold 625,000 Revolution Medicines shares in Q1 2023, an estimated $14.9M.
  • Redmile Group first reported a position in Revolution Medicines in Q1 2020 and held it in 3 quarters.
  • Redmile Group's Revolution Medicines position peaked at $14.9M in Q4 2022.
  • 152 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2023.

Based on Redmile Group's 13F filing for Q1 2023, filed 15 May 2023.